Myriad Genetics expanded the availability of its ultrasensitive tumor-informed Precise MRD test beyond an early access program into broader breast, colorectal, and renal cancer use. The company said it is broadening indications after MONITOR-Breast results in Future Oncology and is planning workflow and evidence-building intended to support wider clinical adoption. In the MONITOR-Breast study, Myriad reported that ctDNA detection during neoadjuvant therapy provided insight into treatment response and helped flag patients at increased residual disease risk. The test is built on tumor-informed, whole-genome sequencing with personalized panels tracking up to 1,000 variants. The expansion suggests Myriad is moving from pilot-stage operational validation toward broader commercialization, using MRD-positive dynamics to refine surveillance and treatment decision-making in multiple oncology settings.